{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:55:21Z","timestamp":1789012521374,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T00:00:00Z","timestamp":1690070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg\/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41\u201381) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4\u201310). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0\u20137), whereas the median PFS among the responders was 12 months (95%CI: 6\u201318). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2\u20133 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit.<\/jats:p>","DOI":"10.3390\/ijms241411829","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:57:30Z","timestamp":1690160250000},"page":"11829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-171X","authenticated-orcid":false,"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-2447","authenticated-orcid":false,"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5016-8729","authenticated-orcid":false,"given":"Vassiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). BCMA in Multiple Myeloma\u2014A Promising Key to Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184088"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2023.41.16_suppl.8007","article-title":"A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): DREAMM-3","volume":"41","author":"Hungria","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"More, S., Offidani, M., Corvatta, L., Petrucci, M.T., and Fazio, F. (2023). Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers, 15.","DOI":"10.20944\/preprints202304.1161.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2021.01.018","article-title":"Real-World Treatment of Patients with Relapsed\/Refractory Myeloma","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMsb1901642","article-title":"The Magic of Randomization versus the Myth of Real-World Evidence","volume":"382","author":"Collins","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(18)32840-X","article-title":"Real-world studies no substitute for RCTs in establishing efficacy","volume":"393","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40487-022-00212-5","article-title":"Real-World Outcomes of Belantamab Mafodotin for Relapsed\/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)","volume":"11","author":"Alegre","year":"2023","journal-title":"Oncol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1026251","DOI":"10.3389\/fonc.2022.1026251","article-title":"Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience","volume":"12","author":"Iula","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"200","author":"Shragai","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Talbot, A., Bobin, A., Tabone, L., Lambert, J., Boccaccio, C., Deal, C., Petillon, M.O., Allangba, O., Agape, P., and Arnautou, P. (2023). Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study. Haematologica.","DOI":"10.1016\/S2152-2650(22)00606-1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"de la Rubia, J., Alonso, R., Clavero, M.E., Askari, E., Garcia, A., Anton, C., Fernandez, M., Escalante, F., Garcia, A., and Rios-Tamayo, R. (2023). Belantamab Mafodotin in Patients with Relapsed\/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers, 15.","DOI":"10.3390\/cancers15112964"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2022-156035","article-title":"Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study","volume":"140","author":"Roussel","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1182\/blood-2022-164929","article-title":"Belantamab Mafodotin (Belamaf) for Relapsed\/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1182\/blood-2022-171077","article-title":"Belantamab Mafodotin in Patients with Relapsed\/Refractory Multiple Myeloma, a Real-World Single Center Experience","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1200\/JCO.2022.40.16_suppl.8060","article-title":"Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed\/refractory multiple myeloma","volume":"40","author":"Becnel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pozzi, S., Bari, A., Pecherstorfer, M., and Vallet, S. (2021). Management of Adverse Events and Supportive Therapy in Relapsed\/Refractory Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13194978"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: A consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1097\/HS9.0000000000000764","article-title":"Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients with Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy","volume":"6","author":"Karalis","year":"2022","journal-title":"Hemasphere"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:17:32Z","timestamp":1760127452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,23]]},"references-count":33,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411829"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411829","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,23]]}}}